Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study

@article{Quelch2017NalmefeneRR,
  title={Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study},
  author={D. Quelch and I. Mick and J. McGonigle and A. Ramos and R. Flechais and M. Bolstridge and E. Rabiner and M. Wall and R. Newbould and B. Steiniger-Brach and Franz van den Berg and M. Boyce and D. Nilausen and L. Sluth and D. Meulien and C. Goltz and D. Nutt and A. Lingford-Hughes},
  journal={Biological Psychiatry},
  year={2017},
  volume={81},
  pages={941-948}
}
BACKGROUND Nalmefene is a µ and δ opioid receptor antagonist, κ opioid receptor partial agonist that has recently been approved in Europe for treating alcohol dependence. It offers a treatment approach for alcohol-dependent individuals with "high-risk drinking levels" to reduce their alcohol consumption. However, the neurobiological mechanism underpinning its effects on alcohol consumption remains to be determined. Using a randomized, double-blind, placebo-controlled, within-subject crossover… Expand
Drinking Levels and Profiles of Alcohol Addicted Rats Predict Response to Nalmefene
Endogenous opiates and behavior: 2017
The Use of Functional Magnetic Resonance Imaging (fMRI) to Test Pharmacotherapies for Alcohol Use Disorders: A Systematic Review.
  • E. Grodin, L. Ray
  • Medicine
  • Alcoholism, clinical and experimental research
  • 2019
...
1
2
3
...

References

SHOWING 1-10 OF 71 REFERENCES
In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism
...
1
2
3
4
5
...